Furthermore, for patients who are on immunosuppressive therapies such as BTK inhibitors for CLL/SLL, NCCN recommends considering PJP and HSV/VZV prophylaxis for patients with additional risk factors while receiving therapy [20]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.